| Literature DB >> 35741301 |
Matteo Antonio Sacco1, Fabrizio Cordasco1, Carmen Scalise1, Pietrantonio Ricci1, Isabella Aquila1.
Abstract
Estimating the post-mortem interval (PMI) is a very complex issue due to numerous variables that may affect the calculation. Several authors have investigated the quantitative and qualitative variations of protein expression on post-mortem biological samples in certain time intervals, both in animals and in humans. However, the literature data are very numerous and often inhomogeneous, with different models, tissues and proteins evaluated, such that the practical application of these methods is limited to date. The aim of this paper was to offer an organic view of the state of the art about post-mortem protein alterations for the calculation of PMI through the analysis of the various experimental models proposed. The purpose was to investigate the validity of some proteins as "molecular clocks" candidates, focusing on the evidence obtained in the early, intermediate and late post-mortem interval. This study demonstrates how the study of post-mortem protein alterations may be useful for estimating the PMI, although there are still technical limits, especially in the experimental models performed on humans. We suggest a protocol to homogenize the study of future experimental models, with a view to the next concrete application of these methods also at the crime scene.Entities:
Keywords: forensic pathology; post-mortem interval; proteins; time of death
Year: 2022 PMID: 35741301 PMCID: PMC9222196 DOI: 10.3390/diagnostics12061490
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Algorithm followed for the selection of papers on PubMed and SCOPUS databases.
Papers selected from the review on animal models, with analysis of the sample examined, number of cases, PMI investigated, method used, marker investigated and results. ↑ increase; ↓ decrease/degradation; - no correlation.
| Authors | Animal | Sample | N. of Cases | Post-Mortem Interval (PMI) Evaluated for Analysis of Marker | Method | Protein Marker Investigated | Correlation of the Protein with Increasing PMI Analyzed | Result |
|---|---|---|---|---|---|---|---|---|
| Geissenberger J et al., 2021 [ | Pigs | Skeletal muscle | 6 | 0–240 h | Western blotting | Alpha-tubulin | Degradation | ↓ |
| Tropomyosin | Stability | - | ||||||
| Wang J et al., 2021 [ | Mice | Skeletal muscle | 60 | 0–96 h | Western blotting | PP2A-B | Degradation | ↓ |
| PP2A-C | Stability | - | ||||||
| Welson NN et al., 2021 [ | Rats | Myocardium | 42 | 0–120 h | Tissue levels measurement | Malonaldehyde (MDA), | Increase | ↑ |
| Superoxide dismutase (SOD) | Decrease | ↓ | ||||||
| Immunohistochemical staining | B cell lymphoma 2 (BCL2) | Staining reduction | ↓ | |||||
| Zhang Y et al., 2020 [ | Rats | Serum | 54 | 6–168 h | ELISA | TN-T | VEGF/HIF-1α showed a significant relation with PMI | |
| Pittner S et al., 2020 [ | Pigs | Skeletal muscle | 8 | 0–14 days | Western blotting | Cardiac troponin T | Degradation | ↓ |
| Tropomyosin | Stability | - | ||||||
| Choi KM et al., 2019 [ | Rats and mice | Skeletal muscle | 25 | 0–96 h | LC/MS–MS analysis | GAPDH | Decrease and degradation | ↓ |
| Procopio et al., 2018 [ | Pigs | Bone | 4 | 1 month-1 year | LC/MS–MS analysis | Bone proteome | Variations in the decay rate of several proteins | |
| Ehrenfellner et al., 2017 [ | Pigs and mice | Muscle tissues | 3 | 0–10 days | Western blotting | Alpha actinin, | Degradation | ↓ |
| Tropomyosin | Stability | - | ||||||
| Procopio et al., 2017 [ | Pigs | Bone | 5 | 12 days–24 months | LC/MS–MS analysis | Alpha-1 antitrypsin Chromogranin-A | Increase | ↑ |
| Fetuin-A | Decrease | ↓ | ||||||
| Hahor et al., 2016 [ | Fishes | Gastrointestinal tracts | - | 0–48 h | Specific activity Assays | Pepsin activity | Decrease | ↓ |
| Protein measurement | Stomach and intestinal protein concentrations in the crude enzyme extracts | |||||||
| Lee et al., 2016 [ | Rats | Kidney | 48 | 0–96 h | Western blotting | Glycogen synthase (GS) | Degradation | ↓ |
| p53 | Stability | - | ||||||
| Pittner et al., 2016 [ | Pigs | Skeletal muscle | 3 | 0–240 h | Western blotting | Titin | Degradation | ↓ |
| Tropomyosin | Stability | - | ||||||
| Foditsch et al., 2016 [ | Pigs | Skeletal muscle | 2 | 0–21 days | Western blotting | Desmin | Degradation | ↓ |
| α-actinin | Stability | - | ||||||
| Boaks et al., 2014 [ | Pigs | Bone | 5 | 0–12 months | Spectrophotometry | Co/NCo proteins (collagenous and non-collagenous) | Reduction | ↓ |
| Kikuchi et al., 2010 [ | Rats | Blood | 90 | 0–7 days | ELISA | HMGB-1 | Increase | ↑ |
| Poloz et al., 2009 [ | Mice | Skeletal muscle | 4 | 0–96 h | Western blotting | CnA | Degradation | ↓ |
| PP2A | Reduction | ↓ | ||||||
| Lung | MARCKS | Reduction | ↓ | |||||
| Curcio et al., 2006 [ | Rats | Brain | - | 4 h | Western blotting | Bag 1 | No correlation | X |
| Sabucedo et al., 2003 [ | Bovines | Myocardium | 3 | 0–6 days | Western blotting | Intact cTnI degraded | Reduction | ↓ |
| Kang et al., 2003 [ | Rats | Brain | 16 | 0–96 h | Calmodulin binding overlay technique (CaMBOT) | Calmodulin (CaM) binding proteins (CaMBPs) | No correlation | X |
| Lung | Western blotting | Ca2+/CaM-dependent kinase II (CaMKII) | No correlation | X | ||||
| Calcineurin A (CNA) | Degradation | ↓ | ||||||
| Lung | Western blotting | Myristoylated alanine-rich C-kinase substrate (MARCKS) | Reduction | ↓ | ||||
| Inducible nitric oxide synthase (iNOS) | No correlation | X |
Papers selected from the review on human models, with analysis of the sample examined, number of cases, PMI investigated, method used, marker investigated and related results. ↑ increase; ↓ decrease/degradation; - no correlation.
| Authors and Year of Publication | Sample | Number of Cases Examined | Post-Mortem Interval (PMI) Evaluated for Analysis of Marker | Method | Marker Analysed | Correlation of the Protein with Increasing PMI | Result |
|---|---|---|---|---|---|---|---|
| Peyron PA et al., 2021 [ | Cerebrospinal fluid | 82 | 2.0–11.8 h | ELISA | Tau | Increase | ↑ |
| Mickleburgh HL et al., 2021 [ | Bone | 4 | Date of burial-3 years after burial | LC/MS–MS analysis | Complement C3 collagen alpha-1(III) chain (CO3A1) | Decrease | ↓ |
| Hu B.-J., 2020 [ | Myocardium | 5 | 1–28 days | Immunohistochemistry | Desmin | Staining reduction | ↓ |
| Pittner S et al., 2020 [ | Skeletal muscle | 2 | Date of burial-105 days after burial | Western blotting | Tropomyosin | Decrease | ↓ |
| Alpha-tubulin | Degradation and decrease | ↓ | |||||
| Pittner S et al., 2020 [ | Skeletal muscle | 3 | 2.4–42 days | Western blotting | Alpha-tubulin | Degradation | ↓ |
| Mazzotti MC et al., 2019 [ | Gingival tissues | 10 | 3–9 days | Immunohistochemistry | Collagen type I protein | Staining reduction | ↓ |
| Choi KM et al., 2019 [ | Skeletal muscle | 3 | 15–>336 h | Western Blotting | GAPDH | Degradation | ↓ |
| Prieto-Bonete G et al., 2019 [ | Bone | 40 | 5–20 years | LC/MS–MS analysis | 275 proteins | Specific proteins have been identified in different PMI | |
| Lesnikova et al., 2018 [ | Liver | 40 | 1–>14 days | Immunohistochemistry | Vimentin | Staining reduction | ↓ |
| Fais et al., 2018 [ | Gingival tissues | 10 | 1–8 days | Immunohistochemistry | Hypoxia inducible factor (HIF-1α) | Decrease | ↓ |
| Pérez-Martínez et al., 2017 [ | Bone | 80 | 5–47 years | HPLC/MS/MS | Collagen type I protein | Decrease | ↓ |
| Ehrenfellner et al., 2017 [ | Skeletal muscle | 3 | 0.5–40 days | Western blotting | Alpha actinin | Degradation | ↓ |
| Tropomyosin | Stability | - | |||||
| Ortmann et al., 2017 [ | Pancreas | 105 | Several h—22 days | Immunohistochemistry | Insulin | Staining reduction | ↓ |
| Thyroid | Calcitonin | ||||||
| Pittner et al., 2017 [ | Skeletal muscle | 2 | - | Western blotting | Desmin | Degradation | ↓ |
| Tropomyosin | Stability | - | |||||
| Campell et al., 2016 [ | Brain | 16 | 6–72 h | Immunoblotting | Talin | Decrease | ↓ |
| Blair et al., 2016 [ | Brain | 2 | 4.5–48 h | Western blotting | Alpha tubulin | Decrease | ↓ |
| β-actin | No correlation | X | |||||
| NeuN | Decrease (not in all examined cases) | ↓ | |||||
| 6 | Immunohistochemistry | GFAP | No correlation | X | |||
| Alpha tubulin | Staining reduction (not in all examined cases) | ↓ | |||||
| Kumar et al., 2016 [ | Myocardium | 60 | 5–230 h | Western blotting | Cardiac troponin-T | Degradation | ↓ |
| Pittner et al., 2016 [ | Skeletal muscle | 40 | 3.5–92.8 h | Western blotting Zymography | Tropomyosin | Stability | - |
| Cardiac troponin-T | Degradation | ↓ | |||||
| Kumar et al., 2016 [ | Myocardium | 6 | 15–189 h | Western blotting | Cardiac troponin-T | Degradation | ↓ |
| Kumar et al., 2015 [ | Myocardium | 5 | 5–230 h | Western blotting | Cardiac troponin-T | Degradation | ↓ |
| Kumar et al., 2015 [ | Myocardium | 9 | 8–88.4 h | Western blotting | Cardiac troponin-T | Degradation | ↓ |
| Sinha et al., 2012 [ | Myocardium | 20 | 0–10 days | SDS-PAGE analysis | Transferrin | Degradation | ↓ |
| Chandana et al., 2009 [ | Brain | 9 | 4–18 h | Western blotting | GFAP | Increase | ↑ |
| Kasuda et al., 2009 [ | Urine | 44 | 6–48 h | ELISA | von Willebrand factor | Increase | ↑ |
| Blood | No correlation | X | |||||
| Tavichakor-ntrakool et al., 2008 [ | Skeletal muscle | 1 | 1.4–48 h | Q-TOF MS/MS | Heat shock protein 27 | Reduction | ↓ |
| Myoglobin | No correlation | X | |||||
| M. creatine kinase | Increase | ↑ | |||||
| LDH assay | LDH activity | Increase | ↑ | ||||
| Uemura et al., 2008 [ | Blood | 164 | 0–72 h | Latex aggregation method | HbA1c | No correlation | X |
| Rate assay | C-reactive protein | ||||||
| Biuret method | Pseudocholine esterase | ||||||
| JSCC standardization | t-Protein | ||||||
| Crecelius et al., 2008 [ | Brain | 3 | 2 h (after autopsy)–48 h | Western blotting | Peroxiredoxin 1 | Reduction | ↓ |
| GFAP | Increase | ↑ | |||||
| Thaik-Oo et al., 2002 [ | Brain | 19 | 1–120 h | - | Vascular endothelial growth factor (VEGF) | Decrease (after 40 h) | ↓ |
| Lungs | Decrease (after 24 h) | ↓ | |||||
| Heart | No correlation | X |
Figure 2Overall frequency of tissue analysis examined in the studies selected for review (%).
Figure 3Overall percentage of studies that evaluated early, intermediate and late PMI.
Figure 4Overall frequency of analysis of the methodologies examined in the studies selected for the review (N=number of studies).
Figure 5Markers that showed more evidence in the studies selected for review.
Figure 6Operating protocol proposed in early PMI (analysis of biological fluids), intermediate PMI (muscle analysis) and late PMI (bone analysis).